Personalized attention +34 96 206 62 98
Free shipping to Iberian Peninsula from 30€
9/10 Rating
Discreet shipping
The Spanish government has recently approved Royal Decree 903/2025, which regulates the use of medical cannabis exclusively in hospitals and under the prescription of specialized physicians. This regulation aims to ensure that treatments are applied following scientific standards and under professional supervision.
The decree states that medical cannabis preparations must be produced in authorized hospital pharmacies, ensuring strict quality control and precise dosing of THC and CBD. With this measure, Spain takes a major step toward regulating cannabis for therapeutic purposes.
Key points of Royal Decree 903/2025 on medical cannabis in Spain
Royal Decree 903/2025 establishes that medical cannabis can be prescribed only by specialist doctors for specific conditions, when there is documented clinical justification for its use. This measure aims to ensure that patients receive safe, standardized, and professionally supervised treatments.
Additionally, medical cannabis preparations must be made exclusively in authorized hospital pharmacies, following strict criteria for quality, composition, and dosing of active ingredients like THC and CBD. The regulation is flexible regarding therapeutic indications: while it initially mentions conditions such as refractory chronic pain, refractory epilepsy, multiple sclerosis–related spasticity, and chemotherapy-induced nausea, the list may expand as new scientific evidence emerges and the Spanish Agency for Medicines and Health Products (AEMPS) publishes clinical monographs.
The decree also requires laboratories to document and audit the manufacturing and distribution of standardized cannabis-based preparations, ensuring full traceability and product safety. In this way, Spain is building a robust regulatory framework to normalize the use of medical cannabis, giving patients access to innovative, evidence-based therapies under professional supervision.
Why was medical cannabis approved? The benefits of CBD
CBD (cannabidiol) is one of the main cannabinoids found in the cannabis plant. Unlike THC, it does not cause psychoactive effects. Its approval for hospital use is based on its therapeutic potential supported by recent scientific research, suggesting it may serve as an effective complementary treatment for several medical conditions.
Among the most notable benefits of CBD, as reported by studies and patients, are:
- Reduced anxiety and stress: Clinical trials and reviews indicate that CBD can modulate receptors related to anxiety, helping to improve emotional well-being.
- Chronic pain relief: CBD may help reduce pain perception in patients with chronic conditions such as arthritis and neuropathic pain, through anti-inflammatory and neuro-modulatory mechanisms.
- Improved spasticity in multiple sclerosis: Clinical studies have found that certain CBD-based preparations can help decrease muscle stiffness and improve mobility in MS patients.
- Control of refractory epileptic seizures: CBD has shown effectiveness in reducing the frequency and severity of seizures in forms of epilepsy resistant to standard treatments.
- Relief from chemotherapy-related nausea and vomiting: Some patients report better tolerance to cancer treatments when using CBD as an adjunct therapy.
- Anti-inflammatory and neuroprotective properties: Preclinical research suggests that CBD may help reduce inflammation and protect nerve cells, showing potential in various neurological disorders.
Based on these potential benefits, numerous studies, and growing scientific support, Spain is taking major steps toward regulating and implementing medical cannabis, advancing toward safer, standardized, and professionally supervised treatments.
Authorized therapeutic indications
Royal Decree 903/2025 specifies that the use of medical cannabis in Spain will be restricted to specific clinical situations where conventional treatments have proven insufficient. The initial approved indications include:
- Refractory chronic pain: persistent pain that does not respond to traditional treatments.
- Spasticity associated with multiple sclerosis: muscle stiffness and spasms characteristic of the disease.
- Refractory epilepsy: severe forms of epilepsy unresponsive to conventional medications.
- Nausea and vomiting caused by chemotherapy: common side effects among cancer patients.
The Spanish Agency for Medicines and Health Products (AEMPS) has three months to publish clinical monographs detailing the conditions of use, dosage, and possible expansions of these therapeutic indications. These monographs will be added to the National Formulary, serving as a reference for standardized medical cannabis preparations.
It’s important to note that although the Royal Decree initially mentions these four indications, the regulation allows for new therapeutic conditions to be added in the future, depending on the progress of scientific evidence and new monographs published by AEMPS.
Composition, preparation, and access to medical cannabis products
Royal Decree 903/2025 establishes that medical cannabis preparations must be produced exclusively in authorized hospital pharmacies, ensuring uniformity, safety, and traceability. This guarantees that patients receive treatments with precise THC and CBD dosing, avoiding variations that could affect treatment safety or effectiveness.
Standardized composition
Each medical cannabis preparation contains precisely controlled amounts of THC and CBD, the main cannabinoids responsible for therapeutic effects. This standardization allows healthcare professionals to adjust dosing accurately, ensuring consistent and safe treatment, particularly for complex conditions such as refractory epilepsy or chronic pain.
The regulation sets minimum and maximum cannabinoid concentration limits depending on the specific medical indication, ensuring every patient receives a product that meets the safety and efficacy standards required by hospitals and the Spanish Agency for Medicines and Health Products (AEMPS). This strict control also facilitates treatment monitoring and minimizes risks associated with composition variations.
Manufacturing and quality control
Medical cannabis preparations are produced only in authorized hospital laboratories, guaranteeing that every formula meets the highest safety and efficacy standards. Each product batch is documented and audited, ensuring full traceability from raw materials to final patient dispensing.
During the manufacturing process, rigorous analytical testing is conducted to measure THC and CBD levels and detect possible microbial or heavy metal contamination. This ensures that all preparations are safe and consistent, minimizing any potential health risks for patients.
In addition, the entire production and distribution chain is monitored and regulated according to health standards, complying with AEMPS quality protocols and ensuring that every patient receives a reliable, standardized, and high-quality treatment.
Access and treatment monitoring
Access to medical cannabis in Spain is strictly regulated. Patients must receive a prescription from specialized physicians who assess the clinical condition and determine the most appropriate dosage and form of administration based on the therapeutic indication and expected response.
Ongoing medical and pharmaceutical supervision is a key part of treatment. Healthcare professionals monitor therapeutic efficacy, potential side effects, and dosage adjustments to ensure each patient receives the maximum benefits safely. This continuous follow-up allows treatments to be adapted to disease progression and individual tolerance.
Approved administration forms include CBD oils, capsules, standardized extracts, and oral solutions, designed to enable accurate dosing and improve treatment adherence. Each format is selected individually based on the patient’s medical condition, comfort, and the required speed of action.
This comprehensive approach ensures that hospital-based medical cannabis is used safely, effectively, and under supervision—laying the foundation for greater trust in its use within the Spanish healthcare system.
Future outlook and potential expansion
Royal Decree 903/2025 not only regulates the use of medical cannabis in hospitals but also creates a flexible framework that allows for expanding therapeutic indications as scientific evidence advances. As more studies on CBD and other cannabinoids are conducted, new conditions such as endometriosis, fibromyalgia, or neuropathic pain may benefit from these treatments under medical supervision.
The accumulation of clinical data and hospital experience will help reduce the stigma surrounding medical cannabis, promoting its integration into mainstream medical practice. This opens the door for patients to access standardized and safe CBD products with proven therapeutic potential and professional oversight.
With the combination of scientific evidence, regulation, and professional supervision, Spain is making a significant step toward a future where medical cannabis becomes a reliable and accessible treatment option for an increasing number of patients.
The outlook is promising: as science and regulation continue to progress, the use of CBD products and other medical cannabis derivatives is expected to become more normalized, offering safer, more effective, and widely accepted therapeutic options within the healthcare system.
